Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
Biocorrx Inc (BICX) pioneers implantable therapies for substance abuse treatment through FDA-approved naltrexone solutions and comprehensive recovery programs. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access timely reports on trial progress, intellectual property developments, and partnership announcements directly impacting the addiction treatment landscape. Our curated collection includes earnings disclosures, research collaborations with institutions like the National Institute on Drug Abuse, and analyses of market-moving developments in medication-assisted therapies.
Key updates cover three critical areas: clinical research validating long-acting implant efficacy, regulatory filings for expanded treatment applications, and strategic partnerships enhancing patient access to integrated recovery programs. Bookmark this page to monitor how Biocorrx's patented technologies address opioid and alcohol addiction through sustained-release pharmaceutical innovations.
BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
